Trial site
Azienda Sanitaria Locale Napoli 2 Nord
Frattamaggiore, 80027, ItalyNot linked to an institution yet
- 11running trials
- 1closed trial
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 24 trials
- Phase 2/32 trials
- Phase 41 trial
- Status
- Recruiting5 trials
- Active, not recruiting3 trials
- Not yet recruiting3 trials
- Completed1 trial
- Lead sponsor
- Janssen Research & Development, LLC3 trials
- Azienda Provinciale Per I Servizi Sanitari1 trial
- Azienda Sanitaria Locale Napoli 1 Centro1 trial
- Consorzio Oncotech1 trial
- Daiichi Sankyo Inc.1 trial
- and 5 more
Running trials
Not yet recruiting
The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI
2026-525898-39-00· Phase 2/3· Azienda Sanitaria Locale Napoli 1 Centro· Source
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
2024-516906-47-00· Phase 2/3· Daiichi Sankyo Inc.· Source
Recruiting
CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZED STUDY
2024-517789-41-00· Phase 4· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677· Phase 2· Tyra Biosciences, Inc· Source
Not yet recruiting
Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts
2023-503676-25-01· Phase 2· Azienda Provinciale Per I Servizi Sanitari· Source
Active, not recruiting
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)
2022-500587-35-01· Phase 3· University Of Nottingham· Source
Active, not recruiting
Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer
NCT05578664· Phase 2· Consorzio Oncotech· Source
Recruiting
"APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN".
2022-501894-37-00· Phase 2· Fondazione Radioterapia Oncologica Onlus· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error